Fibroblast Growth Factor 21 in Systemic Lupus Erythematosus

Launched by ASSIUT UNIVERSITY · Feb 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a substance called fibroblast growth factor 21 (FGF-21) in patients with systemic lupus erythematosus (SLE), a chronic condition that affects the immune system and can lead to various health problems, especially in the kidneys. The researchers want to see if measuring levels of FGF-21 can help understand how SLE is affecting a person's body, particularly their kidney health. This is important because many people with SLE experience kidney issues, which can be serious and impact their overall well-being.

To participate in this trial, you must be at least 18 years old and have been diagnosed with SLE based on specific classification criteria. Unfortunately, younger patients (under 18), those with other autoimmune diseases, or individuals with certain liver or cancer conditions cannot join. Participants will likely undergo tests to measure FGF-21 levels and assess their kidney function. This study is still in the planning stages and is not yet recruiting participants, but it aims to gather valuable information that could lead to better management of SLE in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - 1- Patients who will be diagnosed as SLE according to the 2019 EULAR/ACR Classification criteria for Systemic Lupus Erythematosus.
• • 2-SLE Patients \> 18 years old.
• Exclusion Criteria:
• • 1-SLE Patients \< 18 years old. 2- Patients with other rheumatic diseases or overlap syndromes. 3- Patients with malignancy. 4- Patients with liver diseases.